Vol. 10(4), pp. 133-148, July 2022 , 2022.

ISSN: 2384-6151

https://doi.org/10.14662/ijebm2022170

 

 

Full Length Research

 

Analytical review of the financial performance of AstraZeneca PLC and a detailed assessment of its macroeconomics, microenvironment, and justification of its market structure

 

Mary Eke Donald

 

University of Bradford  

 

 

 

Accepted 14 July 2022

Abstract

 

This paper provides insightful knowledge onthe reasons why pharmaceutical companies that produce and sell generic drugs make more profits compared to innovative pharmaceutical companies that produce branded drugs. The result of the comparative analysis carried out on the published annual report of AstraZeneca Plc and Hikma Pharmaceutical Plc showed that due to innovative drugs and patents, innovative pharmaceuticals make more profits from the cost of goods sold. However, generic drug manufacturers have higher returns on capital employed due to low operating expense associated with producing generic drugs whosepatents have either expired or has been invalidated.

 

Keywords: AstraZeneca, Generic drugs, branded drugs, financial analysis, financial ratio, Hikma, pharmaceutical, NHS, covid-19, vaccine

 

Cite This Article As: Donald, M.E (2022). Analytical Review of the Financial Performance of AstraZeneca Plc and a Detailed Assessment of Its Macroeconomics, Microenvironment, and Justification of Its Market Structure. Inter. J. Econ. Bus. Manage.10(4): 133-148